Natera (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 11,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Natera Price Performance

Shares of NASDAQ NTRA opened at $222.82 on Wednesday. The company has a 50 day simple moving average of $205.34 and a 200 day simple moving average of $216.16. The firm has a market cap of $31.91 billion, a PE ratio of -136.70 and a beta of 1.56. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Reflection Asset Management bought a new position in Natera during the 4th quarter worth approximately $29,000. Palladiem LLC bought a new position in Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC bought a new position in Natera during the 3rd quarter worth approximately $32,000. International Assets Investment Management LLC raised its holdings in Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust raised its holdings in Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their price objective on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $270.00 price objective on shares of Natera in a report on Friday, May 8th. BTIG Research lowered their price target on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Natera in a report on Friday. They set a “neutral” rating and a $245.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $256.12.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.